Pediatrix Medical Group (PDC) AI Stock Analysis

Pediatrix Medical Group

(Frankfurt:PDC)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitability and revenue growthThe shift from recent net losses to solid profitability, alongside accelerating revenue, indicates meaningful improvement in operating performance. If maintained, stronger earnings can support investment in clinical capacity, technology, acquisitions, and other initiatives that reinforce Pediatrix’s position in women’s and children’s healthcare.

Negative Factors

Cost and margin pressureRevenue growth has not translated proportionally into gross profit or EBITDA growth, indicating pressure from cost structure or business mix. Continued increases in clinical labor, practice expenses, and corporate costs could limit margin expansion and reduce the earnings benefit of future top-line growth.

Pediatrix Medical Group (PDC) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.40B
Dividend Yield: ―
Average Volume (3M): 62
Price to Earnings (P/E): 16.4
Beta (1Y): 0.11
Revenue Growth: -3.17%
EPS Growth: -4.62%
Country: Germany
Employees: 4,280
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Pediatrix Medical Group Business Overview & Revenue Model

Company Description

Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infan...

Pediatrix Medical Group Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:0.78%|Next Earnings Date:Feb 17, 2027

Earnings Call SentimentPositive

The call was predominantly positive: Pediatrix reported adjusted EBITDA above expectations, revenue and same-unit growth, favorable payer mix and pricing drivers, substantial share repurchases, low leverage, and continued strategic flexibility. Offsetting concerns included lower operating cash flow, higher labor and other operating costs, the reversal of prior collection-related pricing benefits, declines in certain neonatology services, and regulatory and hospital-environment uncertainty.

Positive Updates

Strong Q3 Adjusted EBITDA and Raised Confidence

Q3 adjusted EBITDA was $85 million, or $85.5 million as referenced in the Q&A, and results exceeded management's expectations despite increasing costs in virtually all areas of providing health care. The company narrowed its full-year 2026 adjusted EBITDA outlook to $290 million to $300 million.

Negative Updates

Revenue Cycle Management Tailwind Began to Reverse

The company began to lap the strong tailwind from improved collection activity. Management said this lapping reduced pricing by a little over 100 basis points in the quarter, although it described the current revenue cycle management environment as stable.

Company Guidance

Pediatrix narrowed its full year 2026 outlook to $290 million to $300 million in adjusted EBITDA; management said payer mix may remain stable, hospital administrative fee conversations and successes are expected to continue, and acuity is considered sustainable, although there is variability and factors “do bounce around a bit.” RCM impacted the quarter by a little over 100 basis points and is currently “very stable,” with the company continuing to look for ways to further automate and deliver improvement over the next coming years. Clinical salary growth is expected to remain in that 3%, 3.5% area, while management provided no guidance for 2027, said the 2027 coding rules should be finalized in the next few weeks in November, and said the OBH business is not a material part of the company.

Pediatrix Medical Group Risk Analysis

Pediatrix Medical Group disclosed 41 risk factors in its most recent earnings report. Pediatrix Medical Group reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Pediatrix Medical Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PDC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
THC	84Outperform	$21.75B	7.75	60.60%	―	6.23%	136.09%
UHS	68Neutral	$10.37B	7.49	19.54%	0.44%	8.00%	13.14%
HCA	61Neutral	$98.85B	15.45	-100.45%	0.65%	5.82%	16.59%
ARDT	56Neutral	$1.70B	21.33	5.21%	―	3.34%	-69.26%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYH	42Neutral	$338.46M	-0.54	36.02%	―	-7.84%	-88.93%

* Healthcare Sector Average

Performance Comparison

DE:PDC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PDC	Pediatrix Medical Group, Inc.	25.80	7.70	42.54%
CYH	Community Health Systems	2.10	-1.68	-44.44%
HCA	Hca Healthcare	467.73	-0.75	-0.16%
THC	Tenet Healthcare Corp.	268.89	61.16	29.44%
UHS	Universal Health Services	180.65	-42.57	-19.07%
ARDT	Ardent Health Partners, Inc.	11.73	-2.83	-19.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pediatrix Medical Group AI Stock Analysis